Loading...
Market
Primary Reported Benefit of Wegovy Among Canadian Patients by End of 2025?
2
Resolution / Starting Odds
Weight Loss • 25%
Reduced Heart Attack Risk • 25%
Improved Overall Health • 25%
Other • 25%
Patient surveys or studies published in medical journals
Story
Canada Approves Wegovy as First Treatment to Reduce Nonfatal Heart Attack Risk on November 27, 2024
Nov 27, 2024, 06:47 PM
Canada's health regulator has granted approval for Novo Nordisk's weight loss drug, Wegovy, aimed at reducing the risk of nonfatal heart attacks or myocardial infarctions in certain adults. This marks Wegovy as the first treatment in Canada to simultaneously address obesity and the risk of heart-related conditions for adults with established cardiovascular disease. The announcement was made by the Danish drugmaker on November 27, 2024, highlighting the drug's potential in combating significant health risks associated with obesity.
View original story
Similar markets
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Yes • 50%
No • 50%
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%
Price competitiveness • 25%
Efficacy and safety profile • 25%
Marketing and distribution • 25%
Regulatory support • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below 50,000 • 25%
50,000 to 100,000 • 25%
100,000 to 150,000 • 25%
Above 150,000 • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%